Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome
Open Access
- 31 March 2004
- journal article
- clinical trial
- Published by Elsevier BV in Fertility and Sterility
- Vol. 81 (3), 624-629
- https://doi.org/10.1016/j.fertnstert.2003.08.024
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapyJournal of the Society for Gynecologic Investigation, 2003
- Detection of Insulin Resistance by Simple Quantitative Insulin Sensitivity Check Index QUICKI for Epidemiological Assessment and PreventionJournal of Clinical Endocrinology & Metabolism, 2002
- Clinical Significance of the Insulin Resistance Index as Assessed by Homeostasis Model Assessment.Endocrine Journal, 2001
- RosiglitazoneDrugs, 1999
- Pathogenesis of Type 2 DiabetesDrugs, 1999
- Pharmacological Modulation of Insulin Resistance and Hyperinsulinemia in Polycystic Ovary SyndromeThe Endocrinologist, 1998
- Intraovarian Regulation: The Proposed Role of Insulin-like Growth FactorsAnnals of the New York Academy of Sciences, 1993
- Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndromeClinical Endocrinology, 1992
- Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndromeThe Lancet, 1990
- Hyperinsulinemia in a Population at High Risk for Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1986